AveXis Inc (NASDAQ:AVXS) Files An 8-K

AveXis Inc (NASDAQ:AVXS) hosted a live webcast to report on interim data from the Company’s ongoing Phase 1 clinical trial of AVXS-101 for the treatment of spinal muscular atrophy (“SMA”) Type 1 as of September 15, 2016 (the “Interim Data”).  The Interim Data was presented by Jerry Mendell, M.D., director of the Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital, at the 21st International Annual Congress of the World Muscle Society in Granada, Spain.  A copy of the slides presented during the webcast is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Story continues below

The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

An ad to help with our costs